T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BID
1301
DELISTED
Sotheby's
BID
| $9.26M | ﹤0.01% |
337,996
-13,200
| -4% | -$374K |
|
1302
Allot
ALLT
$388M
| $9.2M | ﹤0.01% |
1,869,170
-3,590
| -0.2% | -$18K |
|
|
JWN
1303
DELISTED
Nordstrom
JWN
| $9.19M | ﹤0.01% |
241,573
-646
| -0.3% | -$28.7K |
|
|
PGTI
1304
DELISTED
PGT, Inc.
PGTI
| $9.18M | ﹤0.01% |
+891,490
| New | +$9.19M |
|
1305
Dick's Sporting Goods
DKS
$18.1B
| $9.14M | ﹤0.01% |
202,934
+1,541
| +0.8% | +$67.2K |
|
1306
Corvus Pharmaceuticals
CRVS
$1.27B
| $8.8M | ﹤0.01% |
634,888
-100
| -0% | -$1.35K |
|
1307
IQVIA
IQV
$39.8B
| $8.69M | ﹤0.01% |
132,970
+5,054
| +4% | +$339K |
|
|
GRMN
1308
Garmin
GRMN
$60.2B
| $8.66M | ﹤0.01% |
204,190
| – | – |
|
|
INVN
1309
DELISTED
Invensense Inc
INVN
| $8.61M | ﹤0.01% |
1,404,660
-1,480,590
| -51% | -$10.2M |
|
1310
Opko Health
OPK
$1.04B
| $8.59M | ﹤0.01% |
919,171
-4,000
| -0.4% | -$40.6K |
|
1311
iShares MSCI India ETF
INDA
$6.58B
| $8.57M | ﹤0.01% |
306,900
| – | – |
|
1312
Nektar Therapeutics
NKTR
$2.57B
| $8.32M | ﹤0.01% |
38,967
+7,040
| +22% | +$1.57M |
|
1313
Navient
NAVI
$867M
| $8.26M | ﹤0.01% |
690,973
-23,400
| -3% | -$298K |
|
1314
Stepan Co
SCL
$1.48B
| $8.21M | ﹤0.01% |
137,888
-1,200
| -0.9% | -$70.5K |
|
1315
Mesa Laboratories
MLAB
$633M
| $8.15M | ﹤0.01% |
+66,290
| New | +$7.14M |
|
|
ABAX
1316
DELISTED
Abaxis Inc
ABAX
| $8.12M | ﹤0.01% |
171,960
-2,700
| -2% | -$122K |
|
1317
Standex International
SXI
$3.97B
| $8.12M | ﹤0.01% |
98,230
+8,500
| +9% | +$697K |
|
|
HZNP
1318
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.11M | ﹤0.01% |
492,485
-10,797
| -2% | -$175K |
|
|
ANSS
1319
DELISTED
Ansys
ANSS
| $7.92M | ﹤0.01% |
87,305
-8,167
| -9% | -$722K |
|
|
PBCT
1320
DELISTED
People's United Financial Inc
PBCT
| $7.91M | ﹤0.01% |
539,227
| – | – |
|
1321
Core Laboratories
CLB
$569M
| $7.78M | ﹤0.01% |
62,800
-2,400
| -4% | -$290K |
|
1322
Regenxbio
RGNX
$704M
| $7.75M | ﹤0.01% |
969,233
-7,700
| -0.8% | -$85.5K |
|
|
HBMD
1323
DELISTED
Howard Bancorp, Inc. Common Stock
HBMD
| $7.74M | ﹤0.01% |
595,317
+7,961
| +1% | +$100K |
|
|
ECHO
1324
EchoStar
ECHO
$26.6B
| $7.72M | ﹤0.01% |
240,040
+629
| +0.3% | +$20.6K |
|
1325
Quanta Services
PWR
$101B
| $7.67M | ﹤0.01% |
331,570
+790
| +0.2% | +$18.3K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.